Insurer Restrictions Cause Delays for US Diabetes Patients Seeking Ozempic

Some patients with type 2 diabetes in the US are facing difficulties in getting reimbursed for drugs like Ozempic as insurers tighten coverage restrictions to discourage doctors from prescribing the medication for weight loss. This trend has led to a decline in US prescriptions, causing delays and disruptions for diabetes patients. Insurers are implementing prior authorization requirements, forcing patients to try other drugs before being allowed to access newer medications. The high cost of these medications and the paperwork burden on physicians are additional challenges. Patients and doctors are preparing for potential changes in coverage terms in January.